Andere Sprachen Johnson & Johnson Berne S.E.

Aktien

853260

US4781601046

000943981

Schlusskurs Berne S.E. Andere Börsenplätze 00:00:00 30.05.2024			% 5 Tage	% 1. Jan.
131,3 ^CHF	-0,57 %		-5,11 %	-0,12 %

30.05.	Sarepta Therapeutics wird Shockwave Medical im S&P MidCap 400 ablösen	MT
29.05.	Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30.05.
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	29.05.
J&J : résultats encourageants dans le soin de la dépression	29.05.
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29.05.
J&J's treatment for depression succeeds in late stage study	29.05.
Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes	29.05.
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29.05.
Sector Update: Health Care Stocks Fall Late Afternoon	28.05.
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	28.05.
Sector Update: Health Care	28.05.
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	28.05.
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	28.05.
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	28.05.
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28.05.
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28.05.
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	28.05.
J&J : rachat d'une biotech suisse dans l'eczéma	28.05.
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	28.05.
J&J acquires rights to skin disorder drug for $1.25 bln	28.05.
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Die Medikamentenpipeline ist für 2024 gut positioniert, sagt J&J CFO

Am 23. Januar 2024 um 18:30 Uhr